Voltage imaging in living cells offers the tantalizing possibility of combining the temporal resolution of electrode-based methods with the spatial resolution of imaging techniques. Our lab has been developing voltage-sensitive fluorophores, or VoltageFluors, that respond to changes in cellular and neuronal membrane potential via a photoinduced electron transfer (PeT)-based mechanism. This unique mechanism enables both the fast response kinetics and high sensitivity required to record action potentials in single trials, across multiple cells without the need for stimuli-triggered averaging. In this chapter, we present a methodology for imaging membrane potential dynamics from dozens of neurons simultaneously in vitro. Using simple, commercially available cameras, illumination sources, and microscope optics in combination with the far-red synthetic voltage-sensitive fluorophore BeRST-1 (Berkeley Red Sensor of Transmembrane potential) provides a readily applied method for monitoring neuronal activity in cultured neurons. We discuss different types of voltage-sensitive dyes, considerations for selecting imaging modalities, and outline procedures for the culture of rat hippocampal neurons and performing voltage imaging experiments with these samples. Finally, we provide an example of how changes to the metabolic input to cultured hippocampal neurons can alter their activity profile.

Amyloid beta (Abeta) 1-42 oligomers accumulate in brains of patients with Mild Cognitive Impairment (MCI) and disrupt synaptic plasticity processes that underlie memory formation. Synaptic binding of Abeta oligomers to several putative receptor proteins is reported to inhibit long-term potentiation, affect membrane trafficking and induce reversible spine loss in neurons, leading to impaired cognitive performance and ultimately to anterograde amnesia in the early stages of Alzheimer's disease (AD). We have identified a receptor not previously associated with AD that mediates the binding of Abeta oligomers to neurons, and describe novel therapeutic antagonists of this receptor capable of blocking Abeta toxic effects on synapses in vitro and cognitive deficits in vivo. Knockdown of sigma-2/PGRMC1 (progesterone receptor membrane component 1) protein expression in vitro using siRNA results in a highly correlated reduction in binding of exogenous Abeta oligomers to neurons of more than 90%. Expression of sigma-2/PGRMC1 is upregulated in vitro by treatment with Abeta oligomers, and is dysregulated in Alzheimer's disease patients' brain compared to age-matched, normal individuals. Specific, high affinity small molecule receptor antagonists and antibodies raised against specific regions on this receptor can displace synthetic Abeta oligomer binding to synaptic puncta in vitro and displace endogenous human AD patient oligomers from brain tissue sections in a dose-dependent manner. These receptor antagonists prevent and reverse the effects of Abeta oligomers on membrane trafficking and synapse loss in vitro and cognitive deficits in AD mouse models. These findings suggest sigma-2/PGRMC1 receptors mediate saturable oligomer binding to synaptic puncta on neurons and that brain penetrant, small molecules can displace endogenous and synthetic oligomers and improve cognitive deficits in AD models. We propose that sigma-2/PGRMC1 is a key mediator of the pathological effects of Abeta oligomers in AD and is a tractable target for small molecule disease-modifying therapeutics.